We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125 Only Relapse

This study has been terminated.
(The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the first two years of patients enrolment)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00926107
First Posted: June 23, 2009
Last Update Posted: November 10, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Hellenic Cooperative Oncology Group
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: October 2011
  Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)